[Combined Efficacy of Dendritic Cell Vaccine and Oncolytic Adenovirus in Colorectal Cancer].

Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE

Publication: Tokyo : Gan To Kagaku Ryohosha
Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-

Dendritic Cells*/immunology ; Colorectal Neoplasms*/therapy ; Colorectal Neoplasms*/immunology ; Adenoviridae*/genetics ; Adenoviridae*/immunology ; Cancer Vaccines*/immunology ; Cancer Vaccines*/therapeutic use ; Oncolytic Viruses*/genetics ; Oncolytic Viruses*/immunology ; Oncolytic Virotherapy*/methods; Humans ; Animals ; Mice ; Tumor Suppressor Protein p53/genetics ; Female ; Male ; Combined Modality Therapy

Dendritic cell(DC)vaccine therapy has been widely studied as cancer immunotherapy that potently induces cytotoxic T lymphocytes. However, their efficacy in clinical practice has not yet been established. We have developed an oncolytic adenovirus OBP-702 carrying the tumor suppressor gene p53 and have demonstrated its therapeutic potential to induce cytopathic effect and activate antitumor immunity via p53 induction. In this study, we investigated the combined effect of p53-transduced DC vaccine and OBP-702 in colorectal cancer.

0 (Cancer Vaccines)
0 (Tumor Suppressor Protein p53)

Date Created: 20241121 Date Completed: 20241121 Latest Revision: 20241121

20241122

39571989